名稱 | C5aR1/β-Arrestin/CHO 細(xì)胞 |
型號(hào) | CBP71384 |
報(bào)價(jià) | 86000 |
特點(diǎn) | C5aR1/β-Arrestin/CHO C5AR1 (Complement C5a Receptor 1) is a Protein Coding gene. Diseases associated with C5AR1 include Hypersensitivity Reaction Type Iii Disease and Mast-Cell Sarcoma. Among its rela |
產(chǎn)品搜索
相關(guān)文章
- MicroRNA或可特異性地殺死攜帶常見突變的癌細(xì)胞
- 【產(chǎn)品推介】T細(xì)胞活化篩選模型
- 科學(xué)家有望利用對(duì)療法敏感性的癌細(xì)胞來清除耐藥性癌細(xì)胞
- HPV分子診斷標(biāo)準(zhǔn)品擴(kuò)容:精準(zhǔn)檢測(cè),實(shí)力升級(jí)
- JCI:華人科學(xué)家發(fā)現(xiàn)促進(jìn)乳腺癌進(jìn)展轉(zhuǎn)移的表觀修飾閱讀者
- 心衰治療靶點(diǎn):BNP/NPR1
- 關(guān)于sigma試劑的使用時(shí)長(zhǎng)相關(guān)說明
- DPCR檢測(cè)試劑盒開發(fā)性能驗(yàn)證
- NKG2A細(xì)胞篩選模型
- 腫瘤細(xì)胞上的DNA排列方式探討
聯(lián)系我們
聯(lián)系人:蔣經(jīng)理
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > GPCR細(xì)胞株 > CBP71384C5aR1/β-Arrestin/CHO 細(xì)胞

- 詳細(xì)內(nèi)容
CBP71384 | |
I. Background | |
C5AR1 (Complement C5a Receptor 1) is a Protein Coding gene. Diseases associated with C5AR1 include Hypersensitivity Reaction Type Iii Disease and Mast-Cell Sarcoma. Among its related pathways are Complement cascade and GPCR downstream signalling. | |
II. Introduction | |
Host Cell: | CHO |
Stability: | 20 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | |
Mycoplasma Status: | Negative |
Storage: | Liquid nitrogen immediately upon delivery |
Application(s): | Functional assay for C5aR1 receptor |
Transducer: | Gi |
Ⅲ. Description of Host Cell Line | |
Organism: | Hamster |
Tissue: | Ovary |
Morphology: | Epithelial |
Growth Properties: | Adherent |
Ⅳ. Representative Data | |
Figure 1.Dose response of Human C5a in C5aR1 β-Arrestin CHO-K1 Cell Line (C8). | |
Figure 2. Inhibition of hC5a-induced Beta-Arrestin Recruitment By hC5a Neutralization Ab in C5aR1 Beta-Arrestin CHO-K1Cells(C8). |